The Antimicrobial Susceptibility Testing Market Report offers a thorough examination of the global market, encompassing crucial trends, drivers, hurdles, and prospects. It delves into various segments like product type, application, end-user, and region to furnish a comprehensive understanding of the market dynamics.
The global Antimicrobial Susceptibility Testing market, valued at USD 3.57 billion in 2023, is anticipated to witness significant growth, projected to reach USD 5.35 billion by 2031, with a steady CAGR of 5.2% during the forecast period from 2024 to 2031. These insights are derived from a comprehensive report titled "Antimicrobial Susceptibility Testing Market Size, Share & Segmentation" released by SNS Insider.
Antimicrobial Susceptibility Testing (AST) plays a critical role in guiding the selection of appropriate antimicrobial therapy for bacterial infections, thereby improving patient outcomes and reducing the emergence of antimicrobial resistance. The market's growth is propelled by factors such as the increasing prevalence of infectious diseases, rising awareness about antimicrobial resistance, and the growing demand for rapid and accurate diagnostic solutions.
Get Free PDF Sample Copy of Report @ https://www.snsinsider.com/sample-request/1897
The report segments the Antimicrobial Susceptibility Testing market based on product, technique, application, end-use, and region:
Product: Manual Tests, Automated Instruments, Consumables & Media.
Technique: Automated AST, Etest Method, Dilution, Disk Diffusion, Others.
Application: Drug Development, Susceptibility Testing, Others.
End-Use: Hospitals, Diagnostic Laboratories, Biotechnology & Pharmaceutical Companies, Others.
Among these segments, the automated instruments segment is expected to witness significant growth during the forecast period, driven by the advantages offered by automated AST systems such as reduced turnaround time, higher throughput, and improved accuracy.
Geographically, North America dominates the Antimicrobial Susceptibility Testing market, attributed to factors such as the high prevalence of infectious diseases, well-established healthcare infrastructure, and increasing investments in antimicrobial resistance surveillance programs. However, the Asia Pacific region is poised to witness rapid growth during the forecast period, fueled by the rising burden of infectious diseases, improving healthcare infrastructure, and growing awareness about the importance of antimicrobial stewardship.
Key players operating in the Antimicrobial Susceptibility Testing market include Bio-Rad, BD, Danaher, Thermo Fisher Scientific, Accelerate Diagnostics, Merck Group, Creative Diagnostics, Alifax, Roche Diagnostics Limited, Synbiosis. These companies are focusing on product innovations, strategic collaborations, and mergers & acquisitions to strengthen their market position and offer advanced AST solutions to end-users.
In conclusion, the global Antimicrobial Susceptibility Testing market presents lucrative growth opportunities driven by the increasing prevalence of infectious diseases and the rising demand for rapid and accurate diagnostic solutions. The report provides valuable insights for stakeholders aiming to capitalize on emerging trends in the market.
Comments